Kamada (KMDA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Kamada stock (KMDA) is currently trading at $8.20. Kamada PE ratio is 24.29. Kamada PS ratio (Price-to-Sales) is 2.72. Analyst consensus price target for KMDA is $13.00. WallStSmart rates KMDA as Underperform.
- KMDA PE ratio analysis and historical PE chart
- KMDA PS ratio (Price-to-Sales) history and trend
- KMDA intrinsic value — DCF, Graham Number, EPV models
- KMDA stock price prediction 2025 2026 2027 2028 2029 2030
- KMDA fair value vs current price
- KMDA insider transactions and insider buying
- Is KMDA undervalued or overvalued?
- Kamada financial analysis — revenue, earnings, cash flow
- KMDA Piotroski F-Score and Altman Z-Score
- KMDA analyst price target and Smart Rating
Kamada
📊 No data available
Try selecting a different time range
KMDA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Kamada (KMDA)
KMDA trades 251% above its Graham fair value of $2.38, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Kamada (KMDA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/book. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
Kamada (KMDA) Key Strengths (2)
Growing significantly faster than its price suggests
Trading at 1.82x book value, attractively priced
Supporting Valuation Data
Kamada (KMDA) Areas to Watch (8)
Earnings declining -14.10%, profits shrinking
Very thin margins with limited operational efficiency
Low profitability relative to shareholder equity
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.72x sales
Solid revenue growth at 14.50% per year
Decent profitability, keeps $11 per $100 revenue
Moderate institutional interest at 48.93%
Kamada (KMDA) Detailed Analysis Report
Overall Assessment
This company scores 53/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 2 register as strengths (avg 9.0/10) while 8 fall into concern territory (avg 4.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Book. Valuation metrics including PEG Ratio (0.63), Price/Book (1.82) suggest the stock is attractively priced.
The Bear Case
The primary concerns are EPS Growth, Operating Margin, Return on Equity. Some valuation metrics including Price/Sales (2.72) suggest expensive pricing. Growth concerns include Revenue Growth at 14.50%, EPS Growth at -14.10%, which may limit upside. Profitability pressure is visible in Return on Equity at 7.64%, Operating Margin at 7.95%, Profit Margin at 11.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 7.64% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 14.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Price/Book) and negatives (EPS Growth, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KMDA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KMDA's Price-to-Sales ratio of 2.72x trades 25% below its historical average of 3.64x (35th percentile). The current valuation is 81% below its historical high of 14.16x set in Feb 2014, and 47% above its historical low of 1.85x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~2.4x, reflecting growing market expectations outpacing revenue growth.
Compare KMDA with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Kamada (KMDA) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Kamada operates as a stable business with moderate growth and solid fundamentals. Revenue reached 180M with 14% growth year-over-year. Profit margins of 11.2% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 764.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 5M in free cash flow and 8M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Kamada push profit margins above 15% as the business scales?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Kamada.
Bottom Line
Kamada offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Kamada(KMDA)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.